Atossa Therapeutics, Inc.
General ticker "ATOS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $84.9M (TTM average)
Atossa Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -20.9%.
Estimated limits based on current volatility of 3.1%: low 2.10$, high 2.34$
Factors to consider:
- Total employees count: 12 (+9.1%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient funding, Operating losses, Dependence on external financing, Uncertain profitability, Operational and conduct risks
- Current price 69.3% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.49$, 15.31$]
- 2026-12-31 to 2027-12-31 estimated range: [6.02$, 14.15$]
Short-term ATOS quotes
Long-term ATOS plot with estimates
Financial data
| YTD | 2025-12-31 |
|---|---|
| Operating Revenue | $0.00MM |
| Operating Expenses | $37.14MM |
| Operating Income | $-37.14MM |
| Non-Operating Income | $2.37MM |
| R&D Expense | $21.18MM |
| Income(Loss) | $-34.77MM |
| Net Income(Loss)* | $-34.77MM |
| Stockholders Equity | $39.35MM |
| Assets | $47.61MM |
| Operating Cash Flow | $-29.76MM |
| Capital expenditure | $0.02MM |
| Investing Cash Flow | $-0.02MM |
| Earnings Per Share** | $-4.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.